RxDoctor Payments Data

William Decker, DO

Pulmonary Disease · Adrian, MINPI 1942205208

Payments from drug & device makers

$10,136in general payments, 2019–2025

Across 578 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Mylan Specialty L.p.$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Boehringer Ingelheim$1K
  • GSK$900
  • Sanofi$581
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$9,93898%
  • Education$1982%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,136 in reported general payments places this provider in the 75th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$179,905
Medicare patients
516
Services billed
1,738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter1,148$915,334
TrikaftaElexacaftor/Tezacaftor/Ivacaft12$326,834
EliquisApixaban65$63,723
Breztri AerosphereBudesonide/Glycopyr/Formoterol91$58,519
Dupixent PenDupilumab15$55,849
Dupixent SyringeDupilumab11$41,103
Albuterol Sulfate HfaAlbuterol Sulfate674$30,107
Spiriva RespimatTiotropium Bromide32$29,666
SymbicortBudesonide/Formoterol Fumarate86$29,470
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate77$25,374
Breo ElliptaFluticasone/Vilanterol58$24,503
XareltoRivaroxaban13$19,793
DuleraMometasone/Formoterol31$16,496
Advair HfaFluticasone Propion/Salmeterol34$15,051
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$13,534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$900$962,0081,246 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,824$87,989177 claims
PfizerEliquis$192$63,72365 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat$1,081$41,59654 claims
Johnson & JohnsonXarelto$232$19,79313 claims
MerckDulera$31$16,49631 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$57$2,96211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Adrian

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →